biologic medicines

Market Access

China’s emergence as an R&D powerhouse means that the country is quickly adding a number of drug candidates to the global pipeline.

News

Belgian biotech UCB has made its second acquisition of the year, buying T-cell engager player Candid Therapeutics for up to $2.2 billion.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.